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The threat of potential pandemic influenza requires a reevaluation of licensed therapies for the prophylaxis or treatment of
avian H5N1 infection that may adapt to man. Among the therapies considered for use in pandemic influenza is the co-
administration of ion channel and neuraminidase inhibitors, both to potentially increase efficacy as well as to decrease the
emergence of resistant isolates. To better understand the potential for drug interactions, a cross-over, randomized, open-label
trial was conducted with amantadine, 100 mg po bid, and oseltamivir, 75 mg po bid, given alone or in combination for 5 days.
Each subject (N=17) served as their own control and was administered each drug alone or in combination, with appropriate
wash-out. Co-administration with oseltamivir had no clinically significant effect on the pharmacokinetics (PK) of amantadine
[mean ratios (90% CI) for AUC0-12 0.93 (0.89, 0.98) and Cmax 0.96 (0.90, 1.02).Similarly, amantadine co-administration did not
affect oseltamivir PK [AUC0-12 0.92 (0.86, 0.99) and Cmax 0.85 (0.73, 0.99)] or the PK of the metabolite, oseltamivir carboxylate
[AUC0-12 0.98 (0.95, 1.02) and Cmax 0.95 (0.89, 1.01)]. In this small trial there was no evidence of an increase in adverse events.
Although many more subjects would need to be studied to rule out a synergistic increase in adverse events, the combination
in this small human drug-drug interaction trial appears safe and without pharmacokinetic consequences. Trial Registration.
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Citation: Morrison D, Roy S, Rayner C, Amer A, Howard D, et al (2007) A Randomized, Crossover Study to Evaluate the Pharmacokinetics of
Amantadine and Oseltamivir Administered Alone and in Combination. PLoS ONE 2(12): e1305. doi:10.1371/journal.pone.0001305
INTRODUCTION
The possible adaptation of avian influenza virus into an easily
transmissible virus in humans, resulting in a potential pandemic of
a magnitude not seen for nearly a century, has resulted in
heightened awareness of influenza therapeutic options.[1] Only
two classes of compounds are presently licensed for the treatment
or prophylaxis of epidemic seasonal influenza, the ion channel
inhibitors amantadine and rimantadine (active only against
influenza A) and the neuraminidase inhibitors, oseltamivir and
zanamavir.[2] Due to the increased resistance of circulating
seasonal influenza strains against amantadine, the intrinsic
resistance of most H5N1 strains, and the rapid emergence of
resistance to ion channel inhibitors, amantadine is not considered
to be a first line agent for use in pandemic influenza disease
resulting from potential human adaptation followed by sustained
human-to-human transmission of H5N1 avian influenza.[3,4,5]
Because of its oral availability, activity against most strains of
H5N1, and extensive safety data, oseltamivir, a prodrug of
oseltamivir carboxylate, is considered the likely drug of choice for
both treatment and prophylaxis for potential pandemic influenza
at this time.[4]
However, as the range of available treatment options has
broadened, the use of combination antiviral therapy has become
standard of care in the management of some viral diseases, most
notably RNA virus such as HIV. Combination antiretroviral
therapy has been shown to be associated with greater and more
prolonged reduction in viral burden and with reduced and delayed
emergence of resistance. As some strains of H5N1 influenza virus
remain sensitive to amantadine, the question has arisen as to
whether the use of the oseltamivir and amantadine in combination
may not represent an additional approach to improve efficacy
outcomes and to prevent the emergence of resistance to either
drug. Recent WHO guidelines for the pharmacological manage-
ment of avian influenza virus infection in humans recommended
that where the virus is sensitive to amantadine, that combination
use of oseltamivir with amantadine could be considered. (WHO/
PSM/PAR/2006.6)
These two classes of drugs have different pharmacological
mechanisms of action and it has been speculated that a
combination of the two agents might improve efficacy outcomes
or increase the resistance barriers. In vitro and animal data has
shown that there is some basis for both of these consider-
ations.[6,7,8] An in vitro study of the combination revealed that the
use of this combination in H5N1 drug-sensitive viruses prevented
amino acid substitutions in the HA, NA or M proteins using
relatively low concentrations of oseltamivir combined with
amantadine, whereas each single agent resulted in some mutations
of variable decreased susceptibility.[8] A second study by the same
group showed that the combination of drugs in vivo was more
effective at lowering viral load and preventing clinical illness and
mortality in mice infected with H5N1 than when either oseltamivir
or amantadine was used alone (Ilyushina NA et al, Amantadine-
Academic Editor: Jeremy Farrar, Oxford University Clinical Research Unit, Viet
Nam
Received August 10, 2007; Accepted August 14, 2007; Published December 12,
2007
Copyright:  2007 Morrison et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: All of the authors except D. Morrison are employees of the two
companies, Roche and Novartis, that jointly financed this study.
Competing Interests: All of the authors except D. Morrison are employees of the
two companies, Roche and Novartis, that jointly financed this study.
* To whom correspondence should be addressed. E-mail: thomasg.evans@
novartis.com
PLoS ONE | www.plosone.org 1 December 2007 | Issue 12 | e1305oseltamivir combination therapy for H5N1 influenza virus
infection in mice. Antiviral therapy, In press.)
Other combinations of drugs used against influenza have been
studied with similar results. Ribavirin and rimantadine have been
shown to have a synergistic effect in vitro in MDCK cells, and
ribavirin and amantadine were synergistic in vivo in mice.[7,9]
Rimantadine and zanamavir, or other combinations of M2 and
neuraminidase inhibitors,[6] have been studied in vitro with
promising results, and a small trial in humans was underpow-
ered.[10]
Line listings obtained by the authors from post-marketing
reports of the use of amantadine (Symmetrel, Novartis) or
oseltamivir (Tamiflu, Roche) have shown that physicians, despite
a lack of data or approval, have used these drugs in combination
or series in treating seriously ill influenza patients.
For these reasons, it appeared prudent to produce data to
evaluate the pharmacokinetics of the two drugs when used in
combination, and to rule out an unexpected adverse event that
may occur at a relatively high frequency. There are no theoretical
considerations, using the known drug metabolism or excretion
pathways of either drug (noting that oseltamivir is the prodrug of
oseltamivir carboxylate), that lead to a prediction of meaningful
pharmocological interactions. Nonetheless, the following trial was
designed to provide some data in humans on the use of the drugs
in combination, and to evaluate the pharmacokinetics of
amantadine and oseltamivir administered alone and in combina-
tion.
METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
A total of 18 healthy subjects were to be enrolled, with
replacement of drop-outs allowed. A single Phase 1 site was used.
The study population was comprised of healthy males and female
ages 18 to 45 years, and in good health as determined by past
medical history, physical examination, vital signs, electrocardio-
gram, and laboratory tests. Female subjects of child bearing
potential were required to use non-prescription protocol-indicated
contraception, or be postmenopausal for at least 1 year prior to
inclusion, as confirmed by a plasma follicle-stimulating hormone
(FSH) concentration of .40 IU/L, or must have been surgically
sterilized at least 6 months prior to screening. The body mass
index (BMI) was required to be within the range of 18–30 kg/m
2,
with a minimum weight of 50 kg.
Subjects were excluded from entry into, or continuation in the
study based on any of the following: if they were smokers
(documented by urine cotinine levels for nicotine exposure);
pregnant or lactating; using any prescription drugs in the 4 week
period prior to dosing or used over-the-counter medication in the
2 week period prior to dosing; had participated in any clinical
investigation in the 4 week period prior to dosing; had a significant
illness within two weeks prior to dosing; had a past medical history
of clinically significant ECG abnormalities, a family history of a
prolonged QT-interval syndrome, autonomic dysfunction, acute
or chronic bronchospastic disease, clinically significant drug
allergy, atopic allergy; had any surgical or medical condition
which may alter the absorption, distribution, metabolism or
excretion of drugs; had evidence of liver disease or liver injury as
indicated by abnormal liver function tests, impaired renal
function, or an abnormal CBC. Exclusion criteria also existed
for a history of immunodeficiency diseases, including a positive
HIV, a positive Hepatitis B surface antigen (HBsAg) or Hepatitis C
test, or a history of drug or alcohol abuse in the 12 months prior to
dosing.
Ethics
All subjects underwent informed consent approved by Bio-Kinetic
Clinical Applications Institutional Review Board , an independent
review Board.
Interventions
Each subject participated in a screening period, three baseline
periods, three 5-day treatment periods, two 5 to 7-day washout
periods, and a study completion evaluation (Table 1). The
duration of the treatment period was chosen to exceed the time
required to reach a steady state concentration for amantadine,
oseltamivir and oseltamivir carboxylate.
During recruitment and the baseline period, the subjects were
informed to refrain from strenuous physical exercise for 7 days
before dosing and until after the study completion, alcohol for
48 hours before dosing until after the study completion evaluation,
or the intake of xanthine (e.g., caffeine) containing food or
beverages 48 hours before dosing.
Subjects were randomized to one of six groups, each containing
3 participants (Table 1). During Period 1, subjects received the
first dose of the assigned study drug(s) on Day 1 and remained
domiciled for the full 5 days of each treatment period. Pre-dose
pharmacokinetic samples were collected on the first day (Day 1) of
each treatment. Pharmacokinetic assessments were performed as
outlined below. The subjects returned to the study site for
Treatment Periods 2 and 3 after a washout period of at least
5 days but no longer than 7 days.
On the evening of Day 4 of each treatment period, subjects
fasted overnight prior to dosing and for 4 hours after drug
administration. Meals were similar in caloric content for all
subjects on the days of dosing. When mealtimes coincided with
bleed times, blood was drawn before the meal was provided.
Study safety laboratories were performed at baseline of each
treatment period and 12 hours after the completion of the last
treatment period. These included: Hemoglobin, hematocrit, WBC
count with differential as percentage and absolute value, RBC
count and platelet count, albumin, alkaline phosphatase, total
bilirubin, calcium, cholesterol, creatinine, CK, GGT, glucose,
Table 1. Treatment sequences
......................................................................
Treatment: Subjects randomized using the following scheme (with a wash-out
period of 5 days between each treatment). In group B 3 subjects were
randomized but only 2 entered.
Treatment
Sequence Sample Size Period 1 Period 2 Period 3
A 3 Treatment 1 Treatment 2 Treatment 3
B 3 (2) Treatment 1 Treatment 3 Treatment 2
C 3 Treatment 2 Treatment 1 Treatment 3
D 3 Treatment 2 Treatment 3 Treatment 1
E 3 Treatment 3 Treatment 1 Treatment 2
F 3 Treatment 3 Treatment 2 Treatment 1
Treatment 1=Amantadine 100 mg BID for five days
Treatment 2=Oseltamivir 75 mg BID for five days
Treatment 3=[Amantadine 100 mg+Oseltamivir 75 mg] BID for five days
doi:10.1371/journal.pone.0001305.t001
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PLoS ONE | www.plosone.org 2 December 2007 | Issue 12 | e1305LDH, inorganic phosphorus, lipase, amylase, potassium, total
protein, AST, ALT, sodium, triglycerides, urea and uric acid.
Urinalysis was conducted for specific gravity, pH, semi-
quantitative ‘‘dipstick’’ evaluation of glucose, protein, bilirubin,
ketones, leukocytes, and blood. A microscopic examination
including RBC, WBC, proteins, and casts was performed
only when dipstick evaluation was positive for WBC, or proteins,
or blood. An ECG was performed at baseline of each
treatment period and 12 hours after the last treatment period
completion.
Pharmacokinetic evaluations and measurements
Blood collection occurred predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and
12 hr on the last day of each Treatment Period (Day 5), and pre-
dose samples prior to morning and evening doses on the first day
of each Treatment Period (Day 1). Plasma (,1.5 mL) was
separated by centrifugation within 60 minutes of blood collection,
and the supernatant plasma carefully transferred into two separate
2-mL screw-cap, polypropylene vials. Plasma samples were
immediately stored, in an upright position at or below 215uC
for amantadine or 270uC for oseltamivir.
Amantadine and acetylamantadine plasma concentrations were
determined using a validated liquid chromatography-tandem mass
spectrometry (LC-MS/MS) method with an LLOQ of approxi-
mately 5.00 ng/mL for each analyte at the CEDRA Corporation
in Austin, TX. Oseltamivir and oseltamivir carboxylate plasma
concentrations were determined using a validated high–perfor-
mance liquid chromatography/mass spectrometry method [11]
with LLOQs of approximately 1 ng/mL and 10 ng/mL, respec-
tively, at Bioanalytical Systems Ltd. in the UK. Performance data
are as given in [12].
Objectives
The study was carried out with the primary endpoint to
characterize the pharmacokinetics in healthy adult volunteers of
amantadine (100 mg BID) and oseltamivir (75 mg BID) when
administered alone or in combination. A secondary objective was
to assess the safety and tolerability of twice daily oseltamivir and
amantadine when given alone and when given in combination;
however, the trial was not powered for adverse event endpoints.
The trial was an open-label, multiple dose, randomized, three-way
crossover study.
Randomization
Randomization was performed by Novartis Drug Supply Man-
agement using a validated system in which each subject was
assigned to one of the 6 study arms. The trial was open label, and
thus no blinding was needed.
Statistical methods
To compare the results of the individual versus combination
therapy arms for both amantadine and oseltamivir, log-trans-
formed PK parameters AUC and Cmax were analyzed by a linear
mixed effect model, with fixed effects from sequence, treatment,
and period, and random effects from subject nested in sequence.
Estimators for the treatment difference, including the correspond-
ing 90% confidence intervals, were obtained based upon the log-
transformed observations. The estimators and confidence intervals
were then ‘‘back transformed’’ to the original scale. The resulting
90% confidence interval of the appropriate treatment mean ratios
were used to explore the drug-drug interactions.
RESULTS
Demographics and study conduct
Recruitment occurred in the Fall of 2006. Only 17 of the 18
subjects were enrolled (out of 27 screened), as one subject dropped
out before the first dose (in arm B, Table 1). There were 4 women
and 13 men, with a mean age of 27.9 (range 22–41). All subjects
were able to go through the entire dosing cohort, with no drop-
outs during the trial. No subject dropped out due to an adverse
event or intolerance of the medications.
Effect of oseltamivir on amantadine pharmac-
okinetics Amantadine concentration-time profiles after
administration of 100 mg BID for five days and during
coadministration with 75 mg oseltamivir BID dosing for five
days are shown in Figure 1. Amantadine AUC0-12 and Cmax
decreased slightly when coadministered with oseltamivir compared
to amantadine administration alone (Table 2). The geometric
mean ratio (GMR) of the AUC0-12 of amantadine, coadministered
with oseltamivir compared to amantadine alone, was 0.93. GMR
of the Cmax and Ctrough were 0.96 and 0.92 , respectively. As
expected for amantadine, the geometric mean values for apparent
clearance (15.6 vs 16.7 L/hr), apparent volume of distribution
(332 vs 326 L), half-life (14.7 vs 13.6 hr) and Tmax (2.1 vs 2.4 hr)
were also similar between amantadine monotherapy versus
combination therapy with oseltamivir.
Effect of amantadine on oseltamivir pharmacokin-
etics Oseltamivir and oseltamivir caroboxylate concentration-
time profiles after administration of 75 mg BID for five days and
during coadministration with 100 mg amantadine BID dosing for
five days are shown in Figures 2 and 3, respectively. Oseltamivir
AUC0-12 and Cmax decreased slightly when coadministered with
amantadine compared to oseltamivir administration alone (Table 3
and 4). The geometric mean ratio (GMR) of the AUC0-12 of
oseltamivir, coadministered with oseltamivir compared to
amantadine alone, was 0.92. GMR of the Ctrough and Cmax were
Figure 1. Plasma amantadine concentrations (mean values6standard
deviation) following administration of 100-mg BID amantadine for
five days (open circles) or 100 mg BID amantadine plus 75 mg BID
oseltamivir (open squares) in 17 healthy volunteers
doi:10.1371/journal.pone.0001305.g001
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lower confidence interval of 0.79), respectively. The AUC0-12 and
Cmax of the active oseltamivir carboxylate also decreased slightly
when coadministered with amantadine compared to oseltamivir
administration alone (Table 4). The geometric mean ratio (GMR)
(90% confidence interval [CI]) of the AUC0-12 of oseltamivir
carboxylate, coadministered with oseltamivir compared to
amantadine alone, was 0.98. GMR of the Cmax and Ctrough were
0.95 and 1.03, respectively. As expected, the geometric mean
values for oseltamivir apparent clearance (465 vs 505 L/hr),
apparent distribution volume (1245 vs 1329 L), half-life (1.85 vs
1.83 hr) and Tmax (0.76 vs 0.85 hr) were also similar between
oseltamivir monotherapy versus combination therapy with
amantadine. In addition, geometric mean values for oseltamivir
carboxylate apparent clearance (21.9 vs 22.3 L/hr), apparent
distribution volume (192 vs 197 L), half-life (6.09 vs 6.15 hr) and
Tmax (3.22 vs 3.07 hr) were similar between oseltamivir
monotherapy versus combination therapy with amantadine.
Safety
Only eight adverse events, all mild, were reported during the trial,
two with amantadine alone, and three with oseltamivir alone or in
combination. One episode of mild upset stomach was associated
with the combination, was mild, and resolved without treatment.
DISCUSSION
Many countries worldwide have stockpiled both amantadine and
oseltamivir for use as either for prophylaxis or treatment of
potential pandemic influenza. Guidelines have also been estab-
lished by WHO for the treatment of persons infected with avian
H5N1 influenza A virus, despite a dearth of information on the
clinical effectiveness of the proposed recommendations. Included
in these guidelines is the statement that ‘‘clinicians might
administer a combination of a neuraminidase inhibitor and an
M2 inhibitor if local surveillance data show that the H5N1 is
known or likely to be susceptible’’. There are, however, no data to
support whether there may be an unanticipated drug-drug-
interaction which might impact on the posology of such a
combination.
Excretory and metabolic processes involved in clearance of
amantadine and oseltamivir are different. Amantadine is primarily
excreted unchanged in the urine by glomerular filtration and
tubular secretion, whereas oseltamivir is extensively converted to
oseltamivir carboxylate by esterases.[13,14] Neither oseltamivir
Table 2. Pharmacokinetics of amantadine after 100-mg BID for five days or when coadministered with 75-mg oseltamivir BID for
five days (N=17)
..................................................................................................................................................
PK Parameters for
Amantadine
N Geometric Means Ratio of Geometric Means 90% Confidence
Intervals
Amantadine
alone
Amantadine +
Oseltamivir
Amantadine
alone
Amantadine +
Oseltamivir
Amantadine + Oseltamivir/
Amantadine alone
Cmax (ng/mL) 17 17 636.2 611.3 0.96 0.90, 1.02
AUCtau (ng.hr/mL) 17 17 6413.6 5992.8 0.93 0.89, 0.98
Clast (ng.hr/mL) 17 17 438.1 401.6 0.92 0.86, 0.98
doi:10.1371/journal.pone.0001305.t002
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Figure 2. Plasma oseltamivir concentrations (mean values6standard
deviation) following administration of 100-mg BID amantadine for
five days (open circles) or 100 mg BID amantadine plus 75 mg BID
oseltamivir (open squares) in 17 healthy volunteers
doi:10.1371/journal.pone.0001305.g002
Figure 3. Plasma oseltamivir carboxylate concentrations (mean
values6standard deviation) following administration of 75-mg BID
oseltamivir for five days (open circles) or 75 mg BID oseltamivir plus
100 mg BID amantadine (open squares) in 17 healthy volunteers
doi:10.1371/journal.pone.0001305.g003
Amnatadine and Oseletamivir
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cytochrome P450 isoforms.
As expected, coadministration with oseltamivir had no mean-
ingful impact on the pharmacokinetics of amantadine. Similarly,
amantadine coadministration did not meaningfully affect oselta-
mivir PK or the PK of metabolite, oseltamivir carboxylate. Except
for minor changes in oseltamivir Cmax and Ctrough, confidence
intervals for geometric mean ratios of all other parameters were
within bioequivalence criteria of 80–125%, and the difference
observed for oseltamivir were not considered clinically meaningful
as the point estimates were near unity and the study size was
relatively small.
In a study conducted with amantadine, plasma acetylamanta-
dine accounted for up to 80% of the concurrent amantadine
plasma concentration in 5 of 12 healthy volunteers. Acetylaman-
tadine was not detected in the plasma of the remaining seven
volunteers (see SymmetrelH package insert) In the current study,
acetylamantadine was not detected in the plasma of any of the
seventeen volunteers that participated in this study. In another
study, after 15 days of amantadine 100 mg b.i.d., the Cmax was
0.4760.11 mg/mL in four of the five volunteers (SymmetrelH
package insert). In this study we report a higher geometric mean of
Cmax of 0.64 mg/mL after 5 days of amantadine 100 mg b.i.d and
a geometric mean Cmax of 0.61 mg/mL when coadministered with
oseltamivir.
Previously reported mean Cmax of 65.2 ng/mL was observed for
oseltamivir and 348 ng/mL for oseltamivir carboxylate after twice
daily oral dosing with 75 mg oseltamivir capsule (Oseltamivir
package insert). In this study we report a geometric mean Cmax of
60.2 ng/mL for oseltamivir and 407.1 ng/mL for oseltamivir
carboxylate following administration of 75 mg BID for five day.
When co-administered with amantadine we observed geometric
mean Cmax of 51.1 ng/mL for oseltamivir and 385.6 ng/mL for
oseltamivir carboxylate. Mean AUC0-12 values observed in this
study (geometric mean of 161.3 ng.hr/mL for oseltamivir and
3429.1 ng.hr/mL for oseltamivir carboxylate) were also slightly
higher than values reported earlier for oseltamivir (112 ng.hr/mL)
and oseltamivir carboxylate (2719 ng.hr/mL). When co-adminis-
tered with amantadine we report geometric mean AUC0-12 of
148.6 ng.hr/mL for oseltamivir and 3369.3 ng.hr/mL for oselta-
mivir carboxylate.
The study did not have sufficient power to examine the
potential increase in adverse events, especially those related to the
CNS. Amantadine is well known to result in alteration of mental
status, especially in the elderly, but that population was not studied
here. The potential for a CNS interaction with neuraminidase
inhibitors remains unproven, although a new precaution has
recently been added to the US label of oseltamivir (http://www.
fda.gov/ohrms/dockets/ac/06/briefing/2006-4254B_09_05-PI-
clean-110906.pdf).
Most H5N1 isolates have been resistant to amantadine.
Recently, the H5N1 isolates have been grouped into two distinct
clades and 3 subclades sub-lineages. These include the clade 1
strains that are insensitive to amantadine and the clade 2 viruses
circulating in Indonesia which show an approximate 50%
resistance to amantadine.[15] It is not known if amantadine
resistant viruses will persist or be replaced by fully susceptible
strains (WHO report 2006). Recently, a subclade has been
reported from China (Fujan), but the amantadine sensitivity of this
strain is not yet clear.
Oseltamivir is effective against all strains of influenza A and B
tested, including H5N1.
The neuraminidase of H5N1 appears to be have increased in
sensitivity over time to NA inhibitors since these viruses emerged
in 1997.[4] Seasonal influenza strains have a low rate of resistance
to oseltamivir-0.33% in adults and 4% in children, although some
studies have reported higher rates in children who may have been
underdosed.[16] In patients with H5N1 infection viral load
appears to be much higher than encountered in seasonal
influenza, and a total of 3 cases have been reported where
reduced susceptibility to oseltamivir was noted.[17,18] These
results highlight not only the need to understand and administer
Table 3. Pharmacokinetics of oseltamivir following 75-mg BID for five days administered alone or when coadministered with 100-
mg amantadine BID for five days (N=17)
..................................................................................................................................................
PK Parameters for
Oseltamivir
N Geometric Means Ratio of Geometric Means 90% Confidence
Intervals
Oseltamivir
alone
Amantadine +
Oseltamivir
Oseltamivir
alone
Amantadine +
Oseltamivir
Amantadine + Oseltamivir/
Oseltamivir alone
Cmax (ng/mL) 17 17 60.2 51.1 0.85 0.73, 0.99
AUCtau (ng.hr/mL) 17 17 161.3 148.6 0.92 0.86, 0.99
Clast (ng.hr/mL) 17 17 1.7 1.6 0.95 0.79, 1.14
doi:10.1371/journal.pone.0001305.t003
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Table 4. Pharmacokinetics of oseltamivir carboxylate following administration of oseltamivir 75-mg BID for five days alone or when
coadministered with 100-mg amantadine BID for five days (N=17)
..................................................................................................................................................
PK Parameters for
Oseltamivir
carboxylate
N Geometric Means Ratio of Geometric Means 90% Confidence
Intervals
Oseltamivir
alone
Amantadine +
Oseltamivir
Amantadine
alone
Amantadine +
Oseltamivir
Amantadine + Oseltamivir/
Oseltamivir alone
Cmax (ng/mL) 17 17 407.1 385.6 0.95 0.89, 1.01
AUCtau (ng.hr/mL) 17 17 3429.1 3369.3 0.98 0.95, 1.02
Clast (ng.hr/mL) 17 17 157.8 162.8 1.03 0.99, 1.08
doi:10.1371/journal.pone.0001305.t004
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PLoS ONE | www.plosone.org 5 December 2007 | Issue 12 | e1305the correct oseltamivir dosage as early as possible but also the need
for continued vigilance in H5N1 infected patients and the need for
additional antiviral agents or combinations.
Combination treatment in mice using equivalent human
therapeutic doses of oseltamivir and amantadine against a lethal
challenge of recombinant amantadine sensitive A/Vietnam/
1203/04 (H5N1) virus protected 90% of the animals in contrast
to dosing of each as a single agent where the mortality protection
level was only 20% (Ilyushina, in press). No benefit of the
combination was observed when infection was performed with an
amantadine-resistant virus. The pharmacological basis for this
beneficial combination of the two therapeutics might be explained
by their targeting different viral proteins (NA and M2) , but this is
not clear at this time.
In summary, the combination of amantadine and oseltamivir
was without evidence of an increase in adverse events (although
underpowered for this endpoint), and there was no clinically
significant effect of either drug on the pharmacokinetic profile of
the other. Data from this limited human volunteer study and the
preliminary animal and in vitro data available on amantadine and
oseltamivir indicate that it would be worthwhile to conduct further
studies using such a combination.
SUPPORTING INFORMATION
Protocol S1 Trial protocol
Found at: doi:10.1371/journal.pone.0001305.s001 (0.17 MB
PDF)
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0001305.s002 (0.05 MB
DOC)
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